These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Therapeutic complement inhibition – from experimental to clinical medicine. Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669 [TBL] [Abstract][Full Text] [Related]
7. Complement in hemolytic anemia. Brodsky RA Blood; 2015 Nov; 126(22):2459-65. PubMed ID: 26582375 [TBL] [Abstract][Full Text] [Related]
8. Complement biology for hematologists. Duval A; Frémeaux-Bacchi V Am J Hematol; 2023 May; 98 Suppl 4():S5-S19. PubMed ID: 36688486 [TBL] [Abstract][Full Text] [Related]
9. Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system. Schmidt CQ; Smith RJH Immunol Rev; 2023 Jan; 313(1):376-401. PubMed ID: 36398537 [TBL] [Abstract][Full Text] [Related]
10. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457 [TBL] [Abstract][Full Text] [Related]
11. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Mastellos DC; Reis ES; Yancopoulou D; Risitano AM; Lambris JD Semin Hematol; 2018 Jul; 55(3):167-175. PubMed ID: 30032754 [TBL] [Abstract][Full Text] [Related]
14. Complement Inhibitors in Clinical Trials for Glomerular Diseases. Zipfel PF; Wiech T; Rudnick R; Afonso S; Person F; Skerka C Front Immunol; 2019; 10():2166. PubMed ID: 31611870 [TBL] [Abstract][Full Text] [Related]
15. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Hanna RM; Barsoum M; Vandross A; Kurtz I; Burwick R Curr Opin Nephrol Hypertens; 2019 May; 28(3):278-287. PubMed ID: 30865166 [TBL] [Abstract][Full Text] [Related]
16. Complement and the prothrombotic state. Schmidt CQ; Schrezenmeier H; Kavanagh D Blood; 2022 Mar; 139(13):1954-1972. PubMed ID: 34415298 [TBL] [Abstract][Full Text] [Related]
17. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy. Vernon KA; Ruseva MM; Cook HT; Botto M; Malik TH; Pickering MC J Am Soc Nephrol; 2016 May; 27(5):1334-42. PubMed ID: 26374608 [TBL] [Abstract][Full Text] [Related]
18. Complement in hemolytic anemia. Brodsky RA Hematology Am Soc Hematol Educ Program; 2015; 2015():385-91. PubMed ID: 26637747 [TBL] [Abstract][Full Text] [Related]
19. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Goodship TH; Cook HT; Fakhouri F; Fervenza FC; Frémeaux-Bacchi V; Kavanagh D; Nester CM; Noris M; Pickering MC; Rodríguez de Córdoba S; Roumenina LT; Sethi S; Smith RJ; Kidney Int; 2017 Mar; 91(3):539-551. PubMed ID: 27989322 [TBL] [Abstract][Full Text] [Related]
20. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition. Varela JC; Brodsky RA Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]